Sarepta Therapeutics Inc. (NASDAQ: SRPT) is -0.90% lower on its value in year-to-date trading and has touched a low of $78.06 and a high of $181.83 in the current 52-week trading range. The SRPT stock was last observed hovering at around $168.95 in the last trading session, with the day’s loss setting it -84.25% off its average median price target of $143.00 for the next 12 months. It is also 62.02% off the consensus price target high of $223.00 offered by 23 analysts, but current levels are -16.03% lower than the price target low of $73.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $84.70, the stock is -50.21% and -44.34% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 11.35 million and changing -49.87% at the moment leaves the stock -41.45% off its SMA200. SRPT registered 29.93% gain for a year compared to 6-month loss of -0.59%. The firm has a 50-day simple moving average (SMA 50) of $159.65 and a 200-day simple moving average (SMA200) of $151.30.
The stock witnessed a 11.85% gain in the last 1 month and extending the period to 3 months gives it a 15.83%, and is -1.51% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.67% over the week and 4.22% over the month.
Sarepta Therapeutics Inc. (SRPT) has around 743 employees, a market worth around $13.41B and $495.10M in sales. Distance from 52-week low is 8.51% and -53.42% from its 52-week high. The company has generated returns on investments over the last 12 months (-47.10%).
Sarepta Therapeutics Inc. (SRPT) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Sarepta Therapeutics Inc. (SRPT) is a “Overweight”. 23 analysts offering their recommendations for the stock have an average rating of 1.80, where 6 rate it as a Hold and 2 think it is a “Overweight”. 14 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Sarepta Therapeutics Inc. is expected to release its quarterly report on 05/12/2021 and quarterly earnings per share for the current quarter are estimated at -$1.8 with sales reaching $148.68M over the same period.The EPS is expected to shrink by -77.80% this year, but quarterly earnings will post 42.20% year-over-year. Quarterly sales are estimated to grow 48.50% in year-over-year returns.
Sarepta Therapeutics Inc. (SRPT) Top Institutional Holders
614 institutions hold shares in Sarepta Therapeutics Inc. (SRPT), with 3.82M shares held by insiders accounting for 4.85% while institutional investors hold 97.03% of the company’s shares. The shares outstanding are 78.50M, and float is at 75.09M with Short Float at 10.53%. Institutions hold 92.33% of the Float.
The top institutional shareholder in the company is Vanguard Group, Inc. (The) with over 7.09 million shares valued at $995.81 million. The investor’s holdings represent 8.99% of the SRPT Shares outstanding. As of Sep 29, 2020, the second largest holder is Capital Research Global Investors with 6.71 million shares valued at $942.47 million to account for 8.50% of the shares outstanding. The other top investors are FMR, LLC which holds 6.34 million shares representing 8.04% and valued at over $890.85 million, while Blackrock Inc. holds 6.91% of the shares totaling 5.46 million with a market value of $766.13 million.
Sarepta Therapeutics Inc. (SRPT) Insider Activity
A total of 13 insider transactions have happened at Sarepta Therapeutics Inc. (SRPT) in the last six months, with sales accounting for 8 and purchases happening 5 times. The most recent transaction is an insider sale by Bratica Joseph, the company’s Principal Financial Officer. SEC filings show that Bratica Joseph sold 1,115 shares of the company’s common stock on Dec 11 at a price of $165.00 per share for a total of $0.18 million. Following the sale, the insider now owns 8140.0 shares.
Sarepta Therapeutics Inc. disclosed in a document filed with the SEC on Dec 08 that Bratica Joseph (Principal Financial Officer) sold a total of 1,125 shares of the company’s common stock. The trade occurred on Dec 08 and was made at $160.00 per share for $0.18 million. Following the transaction, the insider now directly holds 8140.0 shares of the SRPT stock.
Still, SEC filings show that on Aug 10, Wigzell Hans Lennart Rudolf (Director) disposed off 10,000 shares at an average price of $159.00 for $1.59 million. The insider now directly holds 13,792 shares of Sarepta Therapeutics Inc. (SRPT).
Sarepta Therapeutics Inc. (SRPT): Who are the competitors?
The company’s main competitors (and peers) include Ionis Pharmaceuticals Inc. (IONS) that is trading -5.29% down over the past 12 months. PTC Therapeutics Inc. (PTCT) is 32.64% up on the 1-year trading charts. Short interest in the company’s stock has fallen -4.55% from the last report on Nov 12, 2020 to stand at a total of 8.27 million short shares sold with a short interest ratio of 11.62.